MET and non-small cell lung carcinoma: In non-small-cell lung carcinoma (NSCLC), patients with MET amplification as assessed by FISH5–7 had been shown to contribute to resistance to gefitinib therapy and worse prognosis, but benefit from crizotinib6–8.